About RSV Immunoprophylaxis

RSV immunoprophylaxis helps protect eligible infants and children against severe illness caused by respiratory syncytial virus (RSV).

For more information on preventing RSV in babies: Preventing RSV in babies using monoclonal antibodies.

Beyfortus® (nirsevimab)

Beyfortus® (nirsevimab) is a long-acting monoclonal antibody that provides passive immunity against RSV. It is the primary RSV immunoprophylaxis product currently used in Alberta for eligible infants during the RSV season.

Product Information

• Beyfortus® Product Monograph

Program Responsibilities

In-Season Newborn Program

• Offering Beyfortus® (nirsevimab) to eligible families of newborn infants born in Alberta hospitals during RSV season.
• Coordinating administration of Beyfortus® prior to newborn discharge from hospital
• Working with hospital pharmacy departments, which supply and manage Beyfortus® inventory for participating acute care sites
• Providing education and support to healthcare providers and families regarding RSV prevention strategies and Beyfortus® administration.

Pediatric High-Risk RSV Prevention Programs

• Coordinating access to RSV immunoprophylaxis products, including Beyfortus® (nirsevimab) for other infants and children who are not eligible under the In season newborn program but are at high risk of severe RSV infection.
• Notifying referral sources of an infant's or child's eligibility or non-eligibility for RSV immunoprophylaxis.
• Supporting the distribution of RSV immunoprophylaxis products to participating community clinics and other designated points of care.
• Connecting outpatient families with locations where RSV immunoprophylaxis can be administered.
• Providing education and support to healthcare providers, families, and community partners regarding RSV prevention strategies.

Eligibility Criteria & Referrals

In-Season Newborn Program

An infant may be eligible for the In-Season Newborn Program if the infant is born in an Alberta acute care hospital between November 1, 2026 and March 31, 2027. No referral is required however, a physician order is required for the medication to be administered. Eligible infants must be identified and offered Beyfortus® during their birth admission.

For more information about overall provincial eligibility for all infants, please visit: RSV Monoclonal Antibody.

Pediatric High-Risk Program

Infants and children who meet provincial high-risk eligibility criteria may be referred to the Pediatric High-Risk Prevention Program for assessment and coordination of RSV immunoprophylaxis.

Northern Alberta

Edmonton Zone & Area

• Northern Alberta Pediatric RSV Prevention Program

Southern Alberta

Alberta Children's Hospital

• Southern Alberta RSV Prevention Program